SG11201811161YA - Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme - Google Patents

Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme

Info

Publication number
SG11201811161YA
SG11201811161YA SG11201811161YA SG11201811161YA SG11201811161YA SG 11201811161Y A SG11201811161Y A SG 11201811161YA SG 11201811161Y A SG11201811161Y A SG 11201811161YA SG 11201811161Y A SG11201811161Y A SG 11201811161YA SG 11201811161Y A SG11201811161Y A SG 11201811161YA
Authority
SG
Singapore
Prior art keywords
co7d
international
rule
new york
applicant
Prior art date
Application number
SG11201811161YA
Inventor
Agustin Casimiro-Garcia
Joseph Walter Strohbach
David Hepworth
Frank Eldridge Lovering
Chulho Choi
Christophe Philippe Allais
Stephen Wayne Wright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201811161YA publication Critical patent/SG11201811161YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Abstract

International Patent Classification: C07D 403/14 (2006.01) C07D 491/107 (2006.01) C07D 401/14 (2006.01) CO7D 498/10 (2006.01) CO7D 413/14 (2006.01) CO7D 498/18 (2006.01) CO7D 471/08 (2006.01) A61K 31/506 (2006.01) CO7D 487/04 (2006.01) A61P 29/00 (2006.01) CO7D 487/10 (2006.01) (21) International Application Number: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 January 2018 (18.01.2018) WIPO I PCT omit °nolo omm HE mu im Imo oimIE (10) International Publication Number WO 2018/011681 Al PCT/IB2017/054104 (22) International Filing Date: 07 July 2017 (07.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/362,098 14 July 2016 (14.07.2016) US (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, New York, New York 10017 (US). (72) Inventors: CASIMIRO-GARCIA, Agustin; 61 Wood- land Road, Concord, Massachusetts 01742 (US). STRO- HBACH, Joseph Walter; 114 Crockett Creek Drive, Wentzville, Missouri 63385 (US). HEPWORTH, David; 282 Sudbury Road, Concord, Massachusetts 01742 (US). LOVERING, Frank Eldridge; 2 Sutton Pl., Acton, Mass- achusetts 01720 (US). CHOI, Chulho; 56 Mariners Lane, Mystic, Connecticut 06355 (US). ALLAIS, Christophe Philippe; 64 Scotch Cap Road, Unit 114, Quaker Hill, Con- necticut 06375 (US). WRIGHT, Stephen Wayne; 1 Whit- man Lane, Old Lyme, Connecticut 06371 (US). (74) Agent: WALDRON, Roy F. et al.; PFIZER INC., 235 East 42nd Street, MS 235/9/S20, New York, New York 10017 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.170) as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) 1 -1 (54) Title: NOVEL PYRIMIDINE CARBOXAMIDES AS INHIBITORS OF VANIN-1 ENZYME GC 1-1 1-1 O C R ) 1° 0 3 R b Rib (JQ ) IR 1 NJ\"' \ N G xL N R Ra R2b R2a (I) (57) : Compounds, pharmaceutically acceptable salts thereof, are dis- closed wherein the compounds have the structure of (I) as defined in the spec- ification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
SG11201811161YA 2016-07-14 2017-07-07 Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme SG11201811161YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662362098P 2016-07-14 2016-07-14
PCT/IB2017/054104 WO2018011681A1 (en) 2016-07-14 2017-07-07 Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme

Publications (1)

Publication Number Publication Date
SG11201811161YA true SG11201811161YA (en) 2019-01-30

Family

ID=59351004

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811161YA SG11201811161YA (en) 2016-07-14 2017-07-07 Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme

Country Status (14)

Country Link
US (1) US10906888B2 (en)
EP (1) EP3484876A1 (en)
JP (1) JP2019524716A (en)
KR (1) KR20190026902A (en)
CN (1) CN109476645A (en)
AU (1) AU2017296338A1 (en)
BR (1) BR112019000589A2 (en)
CA (1) CA3030381A1 (en)
IL (1) IL263662A (en)
MA (1) MA45656A (en)
MX (1) MX2019000536A (en)
RU (1) RU2019100559A (en)
SG (1) SG11201811161YA (en)
WO (1) WO2018011681A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190254A1 (en) 2017-04-27 2019-10-27 Pharma Mar Sa Antitumoral compounds
ES2927021T3 (en) * 2017-06-12 2022-11-02 Boehringer Ingelheim Int Heteroaromatics as vanin inhibitors
WO2019133445A1 (en) * 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
PL3844161T3 (en) * 2018-08-28 2023-03-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as vanin inhibitors
KR20210056380A (en) 2018-09-04 2021-05-18 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 5- to 7-membered heterocyclic amides as JAK inhibitors
US20220048889A1 (en) * 2018-12-03 2022-02-17 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as vanin inhibitors
KR20210099092A (en) * 2018-12-03 2021-08-11 베링거 인겔하임 인터내셔날 게엠베하 Heteroaromatic Compounds as Vanin Inhibitors
EA202191476A1 (en) 2018-12-03 2021-10-26 Бёрингер Ингельхайм Интернациональ Гмбх HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
CN111388452B (en) * 2020-04-30 2021-10-26 中国药科大学 Adipose tissue targeting peptide P3-chitosan oligomeric lactic acid-polyethylene glycol delivery system and application thereof in nucleic acid drug delivery
TWI811901B (en) * 2020-12-17 2023-08-11 大陸商上海美悅生物科技發展有限公司 A kind of pyrimidine formamide compound and application thereof
CN114933594A (en) * 2022-07-20 2022-08-23 北京科翔中升医药科技有限公司 Fluotriazines compound, pharmaceutical composition and application

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508424A (en) 1993-03-26 1996-04-16 Ortho Pharmaceutical Corporation 4-arylisoindole analgesics
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5811428A (en) 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
EP1094816B1 (en) 1998-07-06 2008-12-10 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
KR100710100B1 (en) 1999-04-15 2007-04-23 브리스톨-마이어스스퀴브컴파니 Cyclic Protein Tyrosine Kinase Inhibitors
DE60035682T2 (en) 1999-04-28 2008-04-30 Sanofi-Aventis Deutschland Gmbh DI-ARYLIC ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS
WO2000071510A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
IL148291A0 (en) 1999-09-16 2002-09-12 Tanabe Seiyaku Co Aromatic nitrogen-containing 6-membered cyclic compounds
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
CN1657523A (en) 2000-04-28 2005-08-24 田边制药株式会社 Cyclic compounds
US20020183316A1 (en) 2000-10-27 2002-12-05 Kevin Pan Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU2002324716A1 (en) 2001-08-17 2003-03-03 Bristol-Myers Squibb Company Patent Department Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
ES2246481T3 (en) 2002-02-27 2006-02-16 Pfizer Products Inc. ACC INHIBITORS
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
AU2003228701A1 (en) 2002-04-25 2003-11-10 Bristol-Myers Squibb Company Spirobarbituric acid derivatives useful as inhibitors of matrix metalloproteases
EP1619185B1 (en) 2003-04-28 2011-06-15 Astellas Pharma Inc. 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
EP1713810B1 (en) 2004-02-04 2010-12-29 NeuroSearch A/S Diazabicyclic aryl derivatives as nicotinic acetylcholine receptor ligands
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
EP1720545B1 (en) 2004-03-03 2014-10-29 ChemoCentryx, Inc. Bicyclic and bridged nitrogen heterocycles
WO2005097751A2 (en) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
NZ550229A (en) 2004-05-12 2009-07-31 Pfizer Prod Inc Proline derivatives and their use as dipeptidyl peptidase IV inhibitors
DE602005004144T2 (en) 2004-06-09 2009-01-29 F. Hoffmann-La Roche Ag OCTAHYDROPYRROLOA 3,4-CYPROLREDIVES AND THEIR USE AS ANTIVIRAL AGENTS
JP2008515972A (en) 2004-10-13 2008-05-15 ニューロジェン・コーポレーション Aryl-substituted 8-azabicyclo [3.2.1] octane compounds as ligands for melanin-concentrating hormone receptors
JP4765545B2 (en) 2004-10-27 2011-09-07 アステラス製薬株式会社 Pharmaceutical composition comprising a benzazepine derivative as an active ingredient
PE20071025A1 (en) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp TRISUSTITUTED AMINE COMPOUND
JP2009526803A (en) 2006-02-15 2009-07-23 エフ．ホフマン−ラ ロシュ アーゲー Heterobicyclic antiviral compounds
PT2463283E (en) 2006-04-20 2014-08-27 Pfizer Prod Inc Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
US20090270435A1 (en) 2006-11-29 2009-10-29 Jeffrey Wayne Corbett Spiroketone Acetyl-CoA Carboxylase Inhibitors
KR100909953B1 (en) 2007-06-15 2009-07-31 한국화학연구원 Triazole derivatives having antifungal activity, method for the preparation thereof and pharmaceutical composition containing same
WO2008157552A2 (en) 2007-06-18 2008-12-24 Mayo Foundation For Medical Education And Research Invertebrate acetylcholinesterase inhibitors
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
MX2010001338A (en) 2007-08-02 2010-04-21 Pfizer Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions.
JP5435592B2 (en) 2008-05-28 2014-03-05 ファイザー・インク Pyrazolospiroketone acetyl CoA carboxylase inhibitor
JP2011521940A (en) 2008-05-28 2011-07-28 ファイザー・インク Pyrazolospiroketone acetyl CoA carboxylase inhibitor
EP2318370A1 (en) 2008-07-29 2011-05-11 Pfizer Inc. Fluorinated heteroaryls
UY32055A (en) 2008-08-19 2010-03-26 Astrazeneca Ab Substituted derivatives of 5-Halo-N2- [substituted] (1-methyl-1H-imidazol-4-yl) pyrimidin-2, -diamine and its pharmaceutically acceptable salts, preparation processes, compositions and applications.
CN102149717B (en) 2008-08-28 2014-05-14 辉瑞大药厂 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
GEP20156239B (en) 2009-03-11 2015-01-26 Pfizer Benzofuranyl derivatives used as glucokinase inhibitors
US20110319379A1 (en) 2009-03-11 2011-12-29 Corbett Jeffrey W Substituted Indazole Amides And Their Use As Glucokinase Activators
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
US8524727B2 (en) 2009-03-30 2013-09-03 Astellas Pharma Inc. Pyrimidine compound
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
EP2427450A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
AR076601A1 (en) 2009-05-21 2011-06-22 Chlorion Pharma Inc PYRIMIDINS AS THERAPEUTIC AGENTS
SG175995A1 (en) 2009-06-05 2011-12-29 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
AR081626A1 (en) 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
DK2565182T3 (en) 2010-04-27 2017-12-04 Mitsubishi Tanabe Pharma Corp New amide derivative and its use as a drug
CN103038229B (en) 2010-05-26 2016-05-11 桑诺维恩药品公司 Heteroaryl compound and using method thereof
SG186850A1 (en) 2010-07-29 2013-02-28 Rigel Pharmaceuticals Inc Ampk-activating heterocyclic compounds and methods for using the same
WO2012031090A2 (en) 2010-09-01 2012-03-08 President And Fellows Of Harvard College Small molecule inhibitors of ebola and lassa fever viruses and methods of use
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US20140018540A1 (en) 2010-12-14 2014-01-16 Electrophoretics Limited Casein kinase 1delta (ck 1delta) inhibitors
WO2013041605A1 (en) 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
MX348311B (en) * 2011-11-11 2017-06-06 Abbvie Inc Nampt inhibitors.
SG10201701101YA (en) 2012-04-02 2017-04-27 Cytokinetics Inc Methods for improving diaphragm function
KR102163931B1 (en) 2012-04-11 2020-10-12 싸이토키네틱스, 인코포레이티드 Improving resistance to skeletal muscle fatigue
CA2885778A1 (en) * 2012-09-25 2014-04-03 Mathilde Muzerelle Alpha hydroxy amides
WO2014085208A1 (en) 2012-11-27 2014-06-05 Merck Sharp & Dohme Corp. 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
CA2987179C (en) * 2015-05-29 2020-08-25 Pfizer Inc. Heterocyclic compounds as inhibitors of vanin-1 enzyme

Also Published As

Publication number Publication date
MX2019000536A (en) 2019-04-01
US20190315715A1 (en) 2019-10-17
CA3030381A1 (en) 2018-01-18
US10906888B2 (en) 2021-02-02
MA45656A (en) 2021-03-24
CN109476645A (en) 2019-03-15
JP2019524716A (en) 2019-09-05
BR112019000589A2 (en) 2019-04-24
EP3484876A1 (en) 2019-05-22
IL263662A (en) 2019-01-31
AU2017296338A1 (en) 2019-01-03
RU2019100559A (en) 2020-07-14
RU2019100559A3 (en) 2020-07-14
WO2018011681A1 (en) 2018-01-18
KR20190026902A (en) 2019-03-13

Similar Documents

Publication Publication Date Title
SG11201811161YA (en) Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
SG11201808990QA (en) Compositions for topical application of compounds
SG11201900799XA (en) Pyridopyrimdinone cdk2/4/6 inhibitors
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201810485SA (en) Substituted carbonucleoside derivatives useful as anticancer agents
SG11201906427QA (en) Heterocyclic spiro compounds as magl inhibitors
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201408186TA (en) Pyridinone and pyridazinone derivatives
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201906417RA (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201808221QA (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201811671XA (en) Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
SG11201900689RA (en) Compounds and compositions and uses thereof
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201809882XA (en) Pharmaceutical combinations for treating cancer